Sign in
Taking peopleNo phase

Bedside bone biopsy compared with usual bone biopsy for diabetic foot bone infection

Compares a bedside bone biopsy with standard biopsy in people with diabetic foot osteomyelitis.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Bedside Bone Biopsy in Diabetic Foot Osteomyelitis
Status
Recruiting
People taking part
320 people, planned
Started
14 Mar 2024
Expected to end
Oct 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bedside blind bone biopsy procedure
Record updated
24 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diabetes and a foot wound where a bone infection (osteomyelitis) is suspected. It compares a bone sample taken at the bedside with the standard way of taking it.

Age
Over 18 years
Sex
All sexes
Disease stage
Diabetic foot with at least one sign of bone infection: a positive probe-to-bone test with X-ray changes, or signs on CT, MRI, white blood cell SPECT/CT or FDG-PET/CT scan.
Earlier treatment
No antibacterial treatment in the 14 days before joining. No antibiotic treatment in the last 15 days before the bone sample.

Main reasons for not taking part

  • Urgent need for surgery
  • Severe lack of blood flow to the leg that cannot be fixed by a procedure to restore blood flow
  • Bone infection in the area of a Charcot foot
  • Not expected to live at least 1 year
  • Pregnant or breastfeeding women; no French social insurance or only State medical aid (AME)

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients eligible for inclusion in this study must fulfill all of the following criteria:
  • Aged >18 years
  • Diabetes mellitus
  • At least one of the following signs of osteomyelitis according to IWGDF 2019 guidelines:; A positive probe to bone test and abnormalities on plain X-ray suggestive for osteomyelitis Signs of osteomyelitis on CT-scan and/or MRI and/or white blood cell SPECT/CT and/or FDG-PET/CT-scan
  • Absence of antibacterial therapy within 14 days before inclusion

Who cannot take part

  • Urgent need for surgery
  • Subjects that (are likely to) undergo surgical or percutaneous revascularization are not excluded
  • Antibiotic treatment in the last 15 days before bone biopsy
  • Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
  • Critical limb ischemia which cannot be corrected by revascularization procedure
  • Osteomyelitis in the area of the Charcot foot destructive process
  • Unlikely to live at least 1 year
  • Not being able to give informed consent and willing to comply with the research protocol
  • Pregnant or breastfeeding women
  • Absence of affiliation to French social insurance
  • State medical aid (AME)
  • Deprivation of liberty, being under a legal protective measure

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

During their lifetime, 15 to 25% of patients with diabetes mellitus will develop a Diabetic Foot Ulcer (DFU) related to neuropathy and/or peripheral arterial disease. DFU is the leading cause of non-traumatic lower-extremity amputation worldwide. Diabetic foot osteomyelitis (DFO), which complicates up to 60% of DFU, is a major trigger of amputation in over 80% of persons with diabetes resulting in subsequent loss of quality of life. It has been shown that medical treatment of DFO may prevent amputations with early diagnosis of osteomyelitis and appropriate use of antibiotics. Empirical antimicrobial treatment is not recommended for DFO as for other chronic infections. Surgically or radiologically acquired bone sample for culture is the reference standard recommended by the International Working Group of Diabetic Foot (IWGDF) to diagnose DFO and to determine the causative bacteria and their susceptibility. However, defining appropriate antimicrobial therapy directed to the causative bacteria in DFO is challenging since it requires bone biopsy (BB) procedures which are underused in clinical practice for various reasons: lack of availability, cost, and delay. Some clinicians also find bone biopsy cumbersome or too invasive.

Read full original descriptionShow less

To overcome these barriers, we have set up for a few years a bedside blind BB procedure performed by diabetologists at the bedside in the clinical ward. Since then, this method has been used in more than 200 patients with DFO in the diabetology departments of Lariboisiere Hospital and Bichat Hospital (Paris). We have recently published our observational data of 79 patients showing that bedside BB is a simple, safe and efficient procedure for the diagnosis of DFO with a similar rate of complete healing at 12 months compared to conventional surgical or radiological bone biopsies. In order to extend and confirm these preliminary and observational results, the aim of this study is to compare the efficiency and safety of bedside BB versus conventional bone biopsy in a randomized controlled trial (RCT) of patients with DFO. Our hypothesis is that bedside BB is non-inferior to conventional bone biopsy in DFO and can be used as a simpler alternative procedure to document DFO

The 2 groups in the trial

  • Bedside blind bone biopsy procedureTreatment being tested

    Bedside blind bone biopsy procedure performed by a physician of the participating center through healthy skin with bone trocar following local and light systemic anesthesia. Samples will be analyzed for microbiology and histopathology

  • Standard bone biopsy procedureExisting treatment, for comparison

    Standard BB procedure (surgical or radiological) performed according to the local standard of care of each participating center and done through healthy skin and under locoregional anesthesia. Samples will be analyzed for microbiology and histopathology

    Treatment: Bedside blind bone biopsy procedure

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bedside Bone Biopsy Versus Conventional Bone Biopsy for Management of Diabetic Foot Osteomyelitis: an Open-label Controlled Randomized Non-inferiority Trial
Plain-language title
Bedside bone biopsy compared with usual bone biopsy for diabetic foot bone infectionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
24 November 2025